Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
This grant funds research aimed at developing new therapeutic approaches for glioblastoma, a type of brain cancer.
About this program
The Glioblastoma Therapeutics Network (GTN) grant supports innovative clinical trials focused on glioblastoma therapeutics. It aims to foster collaboration among researchers and institutions to accelerate the development of effective treatments for this aggressive cancer. The grant is intended for academic institutions, research organizations, and healthcare entities engaged in cancer research and treatment development. Eligible applicants will be required to conduct clinical trials that meet the U19 criteria, which emphasizes the importance of multidisciplinary approaches and the integration of basic, translational, and clinical research. The GTN grant encourages the participation of diverse research teams to enhance the potential for breakthroughs in glioblastoma treatment.
Eligibility
Academic institutions, research organizations, and healthcare entities engaged in cancer research and treatment development.
Requirements
- Conduct clinical trials that meet U19 criteria
- Multidisciplinary collaboration